VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Mato on Managing Side Effects With Ibrutinib/Idelalisib in CLL

Anthony Mato, MD
Published: Wednesday, Aug 24, 2016



Anthony Mato, MD, director of the Chronic Lymphocytic Leukemia Program, University of Pennsylvania, discusses how oncologists can manage adverse events associated with ibrutinib (Imbruvica) and idelalisib (Zydelig) for the treatment of patients with chronic lymphocytic leukemia (CLL).

Recognizing that toxicities can be a reason for discontinuation of treatment is important, Mato explains. The more often that community oncologists administer agents such as ibrutinib and idelalisib, the more likely they will become more familiar with managing the associated toxicities.

If it is unacceptable or medically difficult for a patient to continue medication due to its side effects, there are alternative strategies, Mato says. Researchers will begin exploring other B-cell receptor antagonists that may have improved efficacy with minimal toxicity.


Anthony Mato, MD, director of the Chronic Lymphocytic Leukemia Program, University of Pennsylvania, discusses how oncologists can manage adverse events associated with ibrutinib (Imbruvica) and idelalisib (Zydelig) for the treatment of patients with chronic lymphocytic leukemia (CLL).

Recognizing that toxicities can be a reason for discontinuation of treatment is important, Mato explains. The more often that community oncologists administer agents such as ibrutinib and idelalisib, the more likely they will become more familiar with managing the associated toxicities.

If it is unacceptable or medically difficult for a patient to continue medication due to its side effects, there are alternative strategies, Mato says. Researchers will begin exploring other B-cell receptor antagonists that may have improved efficacy with minimal toxicity.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x